دوره 11، شماره 1 - ( 12-1400 )
جلد 11 شماره 1 صفحات 11-5 |
برگشت به فهرست نسخه ها
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Ilesanmi O, Ayodeji O, Adedosu N, Ojo O, Abejegah C, Jegede T, et al . Mortality among confirmed Lassa Fever cases in Ondo State, Nigeria, January 2017- March 2019: A cross sectional study. JCHR 2022; 11 (1) :5-11
URL: http://jhr.ssu.ac.ir/article-1-692-fa.html
URL: http://jhr.ssu.ac.ir/article-1-692-fa.html
Mortality among confirmed Lassa Fever cases in Ondo State, Nigeria, January 2017- March 2019: A cross sectional study. مجله تحقیقات سلامت. 1400; 11 (1) :5-11
چکیده: (1036 مشاهده)
Background: Lassa fever (LF) is an acute viral haemorrhagic disease endemic in Ondo State, Nigeria. This study aimed to determine the factors associated with mortality among confirmed LF cases.
Methods: A cross sectional study design was used by conducting a retrospective review of the records of all patients who had been treated for LF at the Federal Medical Centre, Owo since 2017 till March 2019. Descriptive statistics were done, case fatality rate was calculated. Chi square tests were used to explore associations. Logistic regression was used to identify the predictors of death. Data were analysed with SPSS version 23.0. P values ≤0.05 were statistically significant.
Results: The median age was 34 years, and the inter-quartile range was 24-48 years. A total of 30 deaths (case fatality rate [CFR] = 10.9%) were recorded, of which 24 (15.5%) were males. Also, the fatality rate increased from 1.6% in 2017 to 10.5% in 2018 and 16.7% in 2019. During peak period, mortality recorded was 15(8.5%) and non-peak periods (April to December), 14(14.9%) was recorded (p=0.104). Fatality was 12.5% (1 out of 8) among pregnant women with 100% foetal death. Patients aged 18-45 years had 0.25 odds of dying (AOR = 0.25; 95%CI= 0.08, 0.76) compared to those aged ≥ 46 years. Those who commenced ribavirin ≥7 days (AOR 4.1; CI = 1.06, 15.42) and those with elevated urea level (AOR 7.5; CI = 2.5, 23.1) have more odds of dying.
Conclusions: A well-coordinated LF outbreak response is needed both at LF peak non-peak periods.
Methods: A cross sectional study design was used by conducting a retrospective review of the records of all patients who had been treated for LF at the Federal Medical Centre, Owo since 2017 till March 2019. Descriptive statistics were done, case fatality rate was calculated. Chi square tests were used to explore associations. Logistic regression was used to identify the predictors of death. Data were analysed with SPSS version 23.0. P values ≤0.05 were statistically significant.
Results: The median age was 34 years, and the inter-quartile range was 24-48 years. A total of 30 deaths (case fatality rate [CFR] = 10.9%) were recorded, of which 24 (15.5%) were males. Also, the fatality rate increased from 1.6% in 2017 to 10.5% in 2018 and 16.7% in 2019. During peak period, mortality recorded was 15(8.5%) and non-peak periods (April to December), 14(14.9%) was recorded (p=0.104). Fatality was 12.5% (1 out of 8) among pregnant women with 100% foetal death. Patients aged 18-45 years had 0.25 odds of dying (AOR = 0.25; 95%CI= 0.08, 0.76) compared to those aged ≥ 46 years. Those who commenced ribavirin ≥7 days (AOR 4.1; CI = 1.06, 15.42) and those with elevated urea level (AOR 7.5; CI = 2.5, 23.1) have more odds of dying.
Conclusions: A well-coordinated LF outbreak response is needed both at LF peak non-peak periods.
فهرست منابع
1. Salami K, Gsell PS, Olayinka A, et al. Meeting report: WHO consultation on accelerating Lassa fever vaccine development in endemic countries. Vaccine. 2020;38(26):4135-4141. [DOI:10.1016/j.vaccine.2020.01.017]
2. Ijarotimi IT, Ilesanmi OS, Aderinwale A, et al. Knowledge of Lassa fever and use of infection prevention and control facilities among health care workers during Lassa fever outbreak in Ondo State, Nigeria. Pan African Medical Journal. 2018; 30: 56.
3. McCormick JB. Lassa fever. In: Saluzzo JF, Dodet B, editors. Emergence and Control of Rodent-borne Viral Diseases. Paris: Elsevier; 1999. pp. 177-795.
4. Kennlyside RA, McCormick JB, Webb PA, et al. Case-control study of Mastomys natalensis and humans in Lassa virus-infected households in Sierra Leone. American Journal of Tropical Medicine and Hygiene. 1983;32(4):829-37. [DOI:10.4269/ajtmh.1983.32.829]
5. Ajayi NA, Nwigwe CG, Azuogu BN, et al. Containing a Lassa fever epidemic in a resource-limited setting: outbreak description and lessons learned from Abakaliki, Nigeria (January-March 2012. International Journal of Infectious Diseases. 2013; 17(11):e1011-6. [DOI:10.1016/j.ijid.2013.05.015]
6. World Health Organization. Lassa fever. Available from: https://www.who.int/news-room/fact-sheets/detail/lassa-fever. Accessed 20 November 2020.
7. Akpede GO, Asogun DA, Okogbenin SA, et al. Lassa fever outbreaks in Nigeria. Expert Review of Anti-Infective Therapy. 2018;16(9):663-666. [DOI:10.1080/14787210.2018.1512856]
8. Olayemi A, Cadar D, Magassouba N, et al. New Hosts of The Lassa Virus. Scientific Reports.2016;3-6. [DOI:10.1038/srep25280]
9. Buba MI, Dalhat MM, Nguku PM, et al. Mortality Among Confirmed Lassa Fever Cases During the 2015-2016 Outbreak in Nigeria. American Journal of Public Health.2018;108(2):262-4. [DOI:10.2105/AJPH.2017.304186]
10. Shehu NY, Gomeri P, Isa SE, et al. Lassa fever 2016 outbreak in Plateau State, Nigeria - The changing epidemiology and clinical presentation. Frontiers in Public Health. 2018;6:232. doi: 10.3389/fpubh.2018.00232 [DOI:10.3389/fpubh.2018.00232]
11. Mofolorunsho KC. Outbreak of lassa fever in nigeria: Measures for prevention and control. Pan Africa Medical Journal. 2016; 23: 210. [DOI:10.11604/pamj.2016.23.210.8923]
12. Asogun DA, Adomeh DI, Ehimuan J, et al. Molecular Diagnostics for Lassa Fever at Irrua Specialist Teaching Hospital, Nigeria: Lessons Learnt from Two Years of Laboratory Operation. PLoS Neglected Tropical Diseases. 2012;6 (9):e1839 [DOI:10.1371/journal.pntd.0001839]
13. NCDC 2020. An update of Lassa fever outbreak in Nigeria. Available at: https://ncdc.gov.ng/diseases/sitreps/ %3fcat%3d5%26name%3dAn+update+of+Lassa+fever+outbreak+in+Nigeria. Accessed September 26 2020.
14. Okokhere P, Colubri A, Azubike C, et al. Clinical and laboratory predictors of Lassa fever outcome in a dedicated treatment facility in Nigeria: an observational cohort study HHS Public Access. Lancet Infectious Diseases. 2018; 18(6):684-695. [DOI:10.1016/S1473-3099(18)30121-X]
15. Ilori EA, Furuse Y, Ipadeola OB, , et al. Epidemiologic and Clinical Features of Lassa Fever Outbreak in Nigeria, January 1-May 6, 2018. Emerging Infectious Diseases. 2019; 25(6):1066-1074. [DOI:10.3201/eid2506.181035]
16. NCDC, 2020. Technical guidelines for integrated disease surveillance and response in Nigeria. Available at: http://www.ncdc.gov.ng/ themes/common/docs/protocols/4_1476085948.pdf. Accessed September 26, 2020.
17. NCDC, 2020. Lassa fever Situation Report: 2020 Week 7. 2020.Available at: https://www.ncdc.gov.ng/ themes/commonfiles/sitreps/6972c8ce98679587edf51016e9ab4051.pdf. Accessed September 26, 2020.
18. Ehichioya, DU, Hass M, Becker-Ziajar B, et al. Current molecular epidemiology of Lassa virus in Nigeria. Journal of Clinical Microbiology. 2011; 49: 1157-1161 [DOI:10.1128/JCM.01891-10]
19. Akpede GO, Asogun DA, Okogbenin SA, et al. Caseload and Case Fatality of Lassa Fever in Nigeria, 2001-2018: A Specialist Center's Experience and Its Implications. Frontiers in Public Health. 2019; 25. [DOI:10.3389/fpubh.2019.00251]
20. Asogun D, Okokhere PO, Okogbenin S,. Lassa fever awareness and practices in a Nigerian rural community. International Journal of Infectious Diseases. 2010; 14(1). e20 [DOI:10.1016/j.ijid.2010.02.1950]
| بازنشر اطلاعات | |
 |
این مقاله تحت شرایط Creative Commons Attribution 4.0 International License قابل بازنشر است. |
